54023-06-2

Basic information

• Product Name: 5-(3-AMINOPHENYL)FURAN-2-CARBOXYLIC ACID METHYL ESTER
• Synonyms: SALOR-INT L300594-1EA;CBI-BB ZERO/008739;METHYL 5-(3-AMINOPHENYL)FURAN-2-CARBOXYLATE;5-(3-AMINOPHENYL)FURAN-2-CARBOXYLIC ACID METHYL ESTER;METHYL 5-(3-AMINOPHENYL)FURAN-2-CARBOXY&
• CAS NO: 54023-06-2
• Molecular Formula: C₁₂H₁₁NO₃
• Molecular Weight: 217.22
• Mol File: 54023-06-2.mol

Chemical Properties

• Melting Point: 102-106 °C(lit.)
• Boiling Point: 411.2 °C at 760 mmHg
• Flash Point: 202.5 °C
• Appearance: /
• Density: 1.222 g/cm³
• CAS DataBase Reference: 5-(3-AMINOPHENYL)FURAN-2-CARBOXYLIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(3-AMINOPHENYL)FURAN-2-CARBOXYLIC ACID METHYL ESTER(54023-06-2)
• EPA Substance Registry System: 5-(3-AMINOPHENYL)FURAN-2-CARBOXYLIC ACID METHYL ESTER(54023-06-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 54023-06-2(Hazardous Substances Data)

Upstream product

• 2527-99-3 methyl 5-bromo-2-furoate 
• 30418-59-8 3-Aminophenylboronic acid 
• 585-70-6 5-bromo-furan-2-carboxylic acid 
• 13331-27-6 m-nitrobenzene boronic acid 
• 13130-13-7 5-(3-nitro-phenyl)-furan-2-carboxylic acid 
• 41019-37-8 5-(3-nitrophenyl)-furan-2-carboxylic acid methyl ester 

Downstream Products

• 528885-24-7 5-(3-(2-(5-cyclohexyl-1-(3,3-dimethyl-2-oxo-butyl)-2-oxo-1,2-dihydro-3H-1,3,4-benzotriazepin-3-yl)-acetylamino)-phenyl)-furan-2-carboxylic acid 
• 942232-15-7 C₃₄H₃₈N₄O₆ 

Relevant articles and documents

Design, synthesis, and electrophysiological evaluation of NS6740 derivatives: Exploration of the structure-activity relationship for alpha7 nicotinic acetylcholine receptor silent activation

The α7 nicotinic acetylcholine receptor (nAChR) silent agonists, able to induce receptor desensitization and promote the α7 metabotropic function, are emerging as new promising therapeutic anti-inflammatory agents. Herein, we report the structure–activity

Shedding X-ray Light on the Role of Magnesium in the Activity of Mycobacterium tuberculosis Salicylate Synthase (MbtI) for Drug Design

The Mg2+-dependent Mycobacterium tuberculosis salicylate synthase (MbtI) is a key enzyme involved in the biosynthesis of siderophores. Because iron is essential for the survival and pathogenicity of the microorganism, this protein constitutes an attractiv

Optimization of 1,3,4-benzotriazepine-based CCK2 antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretion

Starting from a novel, achiral 1,3,4-benzotriazepine-based CCK2 receptor antagonist, a process of optimization has afforded further compounds of this type that maintain the nanomolar affinity for recombinant, human CCK2 receptors and high selectivity over

(5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1

A series of (5-arylfuran-2-ylcarbonyl)guanidines was synthesized and evaluated for the NHE-1 inhibitory activity and cardiprotective efficacy against ischemia-reperfusion injury. Starting with (5-phenylfuran-2-ylcarbonyl) guanidine 47 with a moderate inhibitory effect on NHE-1, the compounds with various substituents at the phenyl ring were investigated with the aim to optimize the potency. In this study, the 2,5-disubstituted compounds appeared to have better activities than the other analogues, and the 2-methoxy-5- chlorophenyl compound 85 was found as a potent inhibitor of NHE-1 (IC 50 = 0.081 μM). Furthermore, 85 showed a marked reduction of infarct size in the rat myocardial infarction model in vivo and significant improvement of cardiac contractile function in the isolated rat heart ischemia model in vitro.

AMINO ACIDS

Compounds of formula (I): Z’ -CO-A-B-NH-Z (I) wherein: Z is H or an amino protecting group; Z’ is OH, a protected or activated hydroxyl group or C1; A is an optionally substituted C5-6 arylene group; and B is an optionally substituted C5-6 arylene group.

1, 3, 4-BENZOTRIAZEPIN-2-ONE SALTS AND THEIR USE AS CCK RECEPTOR LIGANDS

This invention relates to pharmaceutically acceptable salts of compounds of formula (I) wherein: W is N or N+-O-; R2 is an optionally substituted C1 to C18 hydrocarbyl group wherein up to three C atoms may optionally be replaced by N, O and/or S atoms. R3 is -(CR11R12)m-X-(CR13R14)p-R9; m is 0, 1, 2, 3 or 4; p is 0, 1 or 2; X is a bond, -CR15=CR16-, -C≡C-, C(O)NH, NHC(O), C(O)NMe, NMeC(O), C(O)O, NHC(O)NH, NHC(O)O, OC(O)NH, NH, O, CO, SO2, SO2NH, C(O)NHNH, R9 is H ; C1 to C6 alkyl ; or phenyl, naphthyl, pyridyl, benzimidazolyl, indazolyl, quinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, indolinyl, isoindolinyl, indolyl, isoindolyl or 2-pyridonyl substituted with -L-Q. R4 is an optionally substituted C1 to C18 hydrocarbyl group wherein up to three C atoms may optionally be replaced by N, O and/or S atoms ; and Such salts are useful, for example, for the treatment of gastrin related disorders.